arrow
Return

Silver Nanocarriers Targeted with a CendR Peptide Potentiate the Cytotoxic Activity of an Anticancer Drug

delete2020-07-27
delete15
delete
OA
AI
A
Allan Tobi
A
Anne‐Mari A. Willmore
K
Kalle Kilk
V
Valeria Sidorenko
G
Gary B. Braun
U
Ursel Soomets
K
Kazuki N. Sugahara
E
Erkki Ruoslahti
T
Tambet Teesalu *
DOI:10.1002/adtp.202000097delete
deleteOriginal
deleteShare
deleteSave
View PDF
Abstract

Abstract

En 中文
Silver nanoparticles (AgNP) can be tracked in cells and tissues by optical imaging and isotopic fingerprinting. AgNPs are particularly useful as endocytosis probes as they can be rapidly dissolved with a biocompatible etching solution to eliminate extracellular NPs.Here, affinity-targeted AgNPs are evaluated as therapeutic carriers of a potent cytotoxic compound, monomethyl auristatin E (MMAE). AgNPs are coated with MMAE via a lysosomal protease cathepsin B sensitive linker and functionalized with a prototypic CendR peptide (RPARPAR) that targets neuropilin-1 (NRP-1). This gives the AgNPs dual tumor specificity as both cathepsin B and NRP-1 are overexpressed in many types of solid tumors. Cellular imaging, flow cytometry, viability assays, and high-performance liquid chromatography-mass spectrometry (HPLC-MS) analysis show that the RPARPAR-MMAE-AgNPs are internalized and induce apoptotic cell death in NRP-1-positive PPC-1 prostate cancer cells while sparing NRP-1-negative M21 melanoma cells. Furthermore, in a mixed culture of PPC-1 and M21 cells, RPARPAR-MMAE-AgNP treatment selectively eliminates NRP-1-positive PPC-1 cells. The study demonstrates that affinity-targeted AgNPs can be used as carriers to selectively deliver and potentiate the activity of cytotoxic compounds in vitro, and that treatment with a biocompatible etching solution can be used to control the internalization and, thus, the cytotoxicity of these AgNPs.
Keywords:
homing peptides
monomethyl auristatin e
neuropilin-1
silver nanoparticles
C-end Rule
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

A
Advanced Therapeutics
IF:
2.6
Papers:
1.1K
Citations:
3.0K

Organization

C
Columbia University
Scholars:
7.1W
Papers: 6.4W
Citations: 263
U
University of Tartu
Scholars:
1.1W
Papers: 7.5K
Citations: 1.5W
S
Sanford Burnham Prebys Medical Discovery Institute
Scholars:
3.6K
Papers: 2.5K
Citations: 6.7K
researcher View more organizations